Acceleron Pharma Receivables

Acceleron Pharma posts a receivables of $34M as of September 2021. That compares with $23M in the prior-year period — up 51.6% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Acceleron Pharma's receivables was $23M. The latest reading is $34M — a 51.6% year-over-year increase (period ending September 2021). Use the history and growth charts on this page for a longer lookback.

Receivables is one piece of Acceleron Pharma's financial statement story. At $34M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for XLRN's receivables usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Acceleron Pharma's other metric pages and overview cover the third.

Judging Acceleron Pharma against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in receivables easier to interpret. Start with $34M here, then scan peer and history charts to see if the gap is persistent.